Brookline Capital Markets Comments on SABS FY2026 Earnings

Key Points

• Brookline Capital Markets cut its FY2026 EPS estimate for SAB Biotherapeutics to a loss of $1.16 per share from a loss of $1.08; the consensus estimate is a loss of $1.17.
• SAB reported a quarterly loss of $0.24 per share, narrower than analysts’ expected loss of $0.27. Brookline projects the company could reach profitability in FY2029.
• Analyst sentiment is moderately positive: nine analysts rate the stock Buy, one Hold and one Sell, with an average price target of $12.00.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) - Equities research analysts at Brookline Capital Markets lowered their FY2026 earnings per share (EPS) estimates for shares of SAB Biotherapeutics in a research note issued to investors on Thursday, November 5th. Brookline Capital Markets analyst K. Raja now expects that the company will earn ($1.16) per share for the year, down from their previous forecast of ($1.08). The consensus estimate for SAB Biotherapeutics' current full-year earnings is ($1.17) per share. Brookline Capital Markets also issued estimates for SAB Biotherapeutics' Q4 2026 earnings at ($0.27) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.01) EPS, FY2029 earnings at $0.45 EPS and FY2030 earnings at $1.35 EPS.

SABS has been the topic of a number of other reports. Weiss Ratings upgraded shares of SAB Biotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, September 17th. Wall Street Zen raised shares of SAB Biotherapeutics from a "strong sell" rating to a "sell" rating in a report on Monday, August 10th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $12.00.

SAB Biotherapeutics Price Performance

SABS stock opened at $3.10 on Tuesday. SAB Biotherapeutics has a 52 week low of $2.44 and a 52 week high of $5.15. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $3.18 and a two-hundred day simple moving average of $3.66. The firm has a market capitalization of $282.07 million, a P/E ratio of -2.33 and a beta of 0.67.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03.

Institutional Investors Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC boosted its holdings in SAB Biotherapeutics by 700.8% during the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company's stock valued at $24,634,000 after acquiring an additional 5,628,533 shares during the period. Seven Fleet Capital Management LP increased its stake in SAB Biotherapeutics by 47.2% in the second quarter. Seven Fleet Capital Management LP now owns 736,077 shares of the company's stock worth $2,871,000 after purchasing an additional 236,077 shares during the period. Affinity Asset Advisors LLC bought a new stake in shares of SAB Biotherapeutics during the first quarter worth $2,202,000. Monashee Investment Management LLC bought a new stake in shares of SAB Biotherapeutics during the first quarter worth $1,915,000. Finally, DV Trading LLC bought a new stake in shares of SAB Biotherapeutics during the first quarter worth $1,532,000. 7.82% of the stock is owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals' plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.